50 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Therapeutically active compounds and their methods of use
Servier Pharmaceuticals
INHIBITORS OF MUTANT IDH1 AND IDH2
University Of Texas
Therapeutically active compounds and their methods of use
Servier Pharmaceuticals
7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors
Eli Lilly
7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors
Eli Lilly
Inhibiting mutant IDH-1
Forma Therapeutics
Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)
Forma Therapeutics
Inhibiting mutant IDH-1
Forma Therapeutics
Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
Forma Therapeutics
Iridinesulfonamide compound and use method thereof
Chia Tai Tianqing Pharmaceutical Group
Sultam compound and application method thereof
Chai Tai Tianqing Pharmaceutical Group
Therapeutically active compounds and their methods of use
Agios Pharmaceuticals
7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors
Eli Lilly
Therapeutically active compounds and their methods of use
Agios Pharmaceuticals
Fused imidazoles as mIDH1 inhibitors
Bayer Pharma Aktiengesellschaft
Fused amino pyridine as HSP90 inhibitors
Curis
Therapeutically active compounds and their methods of use
Agios Pharmaceuticals
Mutant IDH1 inhibitors
Eli Lilly
Therapeutically active compounds and their methods of use
Agios Pharmaceuticals
Therapeutically active compositions and their methods of use
Agios Pharmaceuticals
Methods and compositions for cell-proliferation-related disorders
Agios Pharmaceuticals
Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
Forma Therapeutics
Tricyclic compounds as inhibitors of mutant IDH enzymes
Merck Sharp & Dohme
Tricyclic compounds as inhibitors of mutant IDH enzymes
Merck Sharp & Dohme
Benzimidazol-2-amines as mIDH1 inhibitors
Bayer Pharma Aktiengesellschaft
5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors
Bayer Pharma Aktiengesellschaft
Tricyclic compounds as inhibitors of mutant IDH enzymes
Merck Sharp & Dohme
N-Methylbenzimidazoles as mIDH1 inhibitors
Bayer Pharma Aktiengesellschaft
Inhibitor of the mutated isocitrate dehydrogenase IDH1 R132H
Bayer Pharma Aktiengesellschaft
Benzimidazol-2-amines as mIDH1 inhibitors
Bayer Pharma Aktiengesellschaft
Benzimidazol-2-amines as MIDH1 inhibitors
Bayer Pharma Aktiengesellschaft
Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
Forma Tm2
Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof
Sunshine Lake Pharma
Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Forma Tm2
Therapeutically active compositions and their methods of use
Agios Pharmaceuticals
Therapeutic compounds and compositions
Agios Pharmaceuticals
Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer
Agios Pharmaceuticals
2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors
Bayer Pharma Aktiengesellschaft
Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Forma Therapeutics
Therapeutically active compounds and their methods of use
Agios Pharmaceuticals
Benzimidazol-2-amines as MIDH1 inhibitors
Bayer Pharma Aktiengesellschaft
1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors
Bayer Pharma Aktiengesellschaft
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
Novartis
Tricyclic compounds as inhibitors of mutant IDH enzymes
Merck Sharp & Dohme
Therapeutically active compounds and their methods of use
Agios Pharmaceuticals
Heterocyclic derivatives and their use in the treatment of neurological disorders
Novartis
Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor
Daiichi Sankyo
Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
National Institutes of Health
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
Albert Einstein College of Medicine
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
Novartis